AtheroNova (OTCBB: AHRO) is an early stage biotech company focused on discovery, research, development and licensing of novel compounds to reduce or regress atherosclerotic plaque deposits. The Company's focus on compounds to reduce or eliminate atherosclerotic plaque deposits addresses the most lucrative segments of the multi-billion dollar prescription drug market: cardiovascular disease and stroke prevention.
AtheroNova announced it has signed an agreement with Frontage Laboratories, Inc. to commence analysis of their AHRO-001 compound and formulate a production plan in preparation for Phase I trials. Frontage Laboratories, Inc., a leading pharmaceutical contract research organization, was chosen based on previous successful relationships with The Company. Work formulating and validating manufacturing procedures ofmanufacturing AHRO-001 tablets will begin immediately.
AtheroNova CEO Thomas W. Gardner commented,
"Frontage has been extremely diligent in dealing with the technical and physical requirements of our AHRO-001 compound and we look forward to commencing our project in the coming days. We are very confident that Frontage will deliver a quality product in a timely manner. We continue to adhere to our vigorous development path and anticipate additional exciting development milestones in the coming months."
View the full press release here.